Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00578175 · ClinicalTrials.gov registry record · Phase 2
Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,851
- Enrollment target
NCT00578175 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 1,851 participants.
The verdict
NCT00578175, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,851 participants
- Enrollment target
Study Summary
The purpose of this observer blinded study is to provide information on vaccine immunogenicity and reactogenicity in comparison with the US standard of care (ProQuad®) when administered with Hepatitis A vaccine and Pneumococcal vaccine.
Interventions
- BIOLOGICAL Havrix®
- BIOLOGICAL Prevnar®
- BIOLOGICAL Priorix-Tetra™ (MMRV vaccine 208136)
- BIOLOGICAL ProQuad®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,851 participants |
| Start Date | 2007-11-20 |
| Est. Completion | 2009-03-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00578175
The ClinicalTrials.gov registry entry for NCT00578175 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1,851 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Havrix® is the first listed.
NCT00578175 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00578175 about?
NCT00578175 is a clinical study titled "Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age". The purpose of this observer blinded study is to provide information on vaccine immunogenicity and reactogenicity in comparison with the US standard of care (ProQuad®) when administered with Hepatitis A vaccine and Pneumococcal vaccine.
What is the current status of trial NCT00578175?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,851 participants. The study started on 2007-11-20. Estimated completion is 2009-03-17.
What interventions are being tested in trial NCT00578175?
The interventions under investigation include: Havrix® (BIOLOGICAL), Prevnar® (BIOLOGICAL), Priorix-Tetra™ (MMRV vaccine 208136) (BIOLOGICAL), ProQuad® (BIOLOGICAL).
Who is sponsoring clinical trial NCT00578175?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.